Posted by Michael Wonder on 17 Sep 2018
Sun Pharma and SPARC announce US FDA approval of Xelpros to treat open-angle glaucoma or ocular hypertension
14 September 2018 - Xelpros (latanoprost ophthalmic emulsion) 0.005% for topical ophthalmic use is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost.
Sun Pharmaceutical Industries today announced U.S. FDA approval for the new drug application of Xelpros (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride, a preservative commonly used in topical ocular preparations. Xelpros is developed using SPARC’s proprietary Swollen Micelle Microemulsion technology.
